Tags

Type your tag names separated by a space and hit enter

[Neuropsychiatric side effects of malarial prophylaxis with mefloquine (Lariam)].
Harefuah. 1999 Jul; 137(1-2):25-7, 87.H

Abstract

There has been an increased incidence of malaria among Europeans returning from Africa and Asia. The relatively new antimalarial mefloquine (Lariam) has become extremely popular due to its efficacy in treating the wide-spread chloroquine-resistant Plasmodium falciparum. Mefloquine is used both for prophylaxis and treatment of malaria and is relatively well tolerated. However, since introduced in 1985, there have been over 100 reports of severe neurologic and psychiatric adverse effects associated with its use, including acute psychosis, affective disorders, acute confusional states and seizures. We describe a 39-year-old woman who developed acute psychosis after being given mefloquine prophylaxis. Adverse effects occur more often after therapeutic rather than prophylactic use, and those with a history of seizures or psychiatric illness are at increased risk of developing these reactions. Physicians should be aware of these possible side effects and prescribe mefloquine only when indicated.

Authors+Show Affiliations

Dept. of Psychiatry, Hadassah Hospital Ein Karem, Jerusalem.

Pub Type(s)

Case Reports
English Abstract
Journal Article

Language

heb

PubMed ID

10959270

Citation

Minei-Rachmilewitz, T. "[Neuropsychiatric Side Effects of Malarial Prophylaxis With Mefloquine (Lariam)]." Harefuah, vol. 137, no. 1-2, 1999, pp. 25-7, 87.
Minei-Rachmilewitz T. [Neuropsychiatric side effects of malarial prophylaxis with mefloquine (Lariam)]. Harefuah. 1999;137(1-2):25-7, 87.
Minei-Rachmilewitz, T. (1999). [Neuropsychiatric side effects of malarial prophylaxis with mefloquine (Lariam)]. Harefuah, 137(1-2), 25-7, 87.
Minei-Rachmilewitz T. [Neuropsychiatric Side Effects of Malarial Prophylaxis With Mefloquine (Lariam)]. Harefuah. 1999;137(1-2):25-7, 87. PubMed PMID: 10959270.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Neuropsychiatric side effects of malarial prophylaxis with mefloquine (Lariam)]. A1 - Minei-Rachmilewitz,T, PY - 2000/8/26/pubmed PY - 2000/9/23/medline PY - 2000/8/26/entrez SP - 25-7, 87 JF - Harefuah JO - Harefuah VL - 137 IS - 1-2 N2 - There has been an increased incidence of malaria among Europeans returning from Africa and Asia. The relatively new antimalarial mefloquine (Lariam) has become extremely popular due to its efficacy in treating the wide-spread chloroquine-resistant Plasmodium falciparum. Mefloquine is used both for prophylaxis and treatment of malaria and is relatively well tolerated. However, since introduced in 1985, there have been over 100 reports of severe neurologic and psychiatric adverse effects associated with its use, including acute psychosis, affective disorders, acute confusional states and seizures. We describe a 39-year-old woman who developed acute psychosis after being given mefloquine prophylaxis. Adverse effects occur more often after therapeutic rather than prophylactic use, and those with a history of seizures or psychiatric illness are at increased risk of developing these reactions. Physicians should be aware of these possible side effects and prescribe mefloquine only when indicated. SN - 0017-7768 UR - https://www.unboundmedicine.com/medline/citation/10959270/[Neuropsychiatric_side_effects_of_malarial_prophylaxis_with_mefloquine__Lariam_]_ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.